Hanall Biopharma (009420.KS)
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, toxic liver disease, chronic hepatitis, liver cirrhosis, male pattern baldness, functional dyspepsia, diabetes, bacterial infections, peripheral vascular disorders, hypertension, chronic heart failure, skin diseases, hypoproteinemia, diabetic polyneuritis, ulcers, high blood pressure, arthritis, endocrine disorders, spasms, insomnia, muscle pain, hypoproteinemia, gastroesophageal reflux disease, allergic rhinitis, conjunctivitis, dermatitis, chronic urticaria, cholesterol cholelithiasis, gastritis, neurological diseases, erectile dysfunction, hyperphosphatemia, urinary tract infection, spastic paralysis, fungal infections, dysmenorrhea, hypercholesterolemia, constipation, abdominal distension, abdominal fermentation in the intestines, neuralgia, capillary weakness, post-phlebitis syndrome, irritable bowel syndrome, spastic colon, and hemorrhoids, as well as vitamin D, vitamin B1, vitamin B12, and calcium deficiency. It develops products in the fields of ophthalmology, immunology, oncology, and neurology, such as HL192 for Parkinson's disease; HL036 for dry eye disease; HL161 for myasthenia gravis, thyroid eye disease, warm autoimmune hemolytic anemia, neuromyelitis optica, immune thrombocytopenia, chronic inflammatory demyelinating polyneuropathy, and graves' disease; and HL187 and HL186 for immuno-oncology. The company was founded in 1973 and is headquartered in Daejeon, South Korea.
Company Info
Highlights
₩1.32T
₩141.00B
₩73.90B
₩24,200.00 - ₩52,000.00
₩44,142.86
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Hanall Biopharma (009420.KS) returned -32.99% year-to-date (YTD) and -17.91% over the past 12 months. Over the past 10 years, 009420.KS returned 9.04% annually, underperforming the S&P 500 benchmark at 10.85%.
009420.KS
-32.99%
-8.16%
-27.86%
-17.91%
14.40%
-0.72%
9.04%
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 009420.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5.43% | -13.37% | -22.24% | 1.09% | -6.67% | -32.99% | |||||||
| 2024 | -30.36% | 12.80% | 7.47% | -3.48% | -12.60% | -1.90% | 14.38% | 13.14% | -3.25% | 14.06% | -18.78% | 7.66% | -12.75% |
| 2023 | -7.87% | -5.06% | 17.85% | 11.72% | 7.56% | -5.90% | 15.42% | -0.84% | 37.47% | -10.41% | 16.75% | 29.72% | 148.88% |
| 2022 | -16.86% | 6.86% | 6.42% | -7.04% | -6.49% | -4.62% | -0.91% | 7.34% | -24.22% | 6.77% | 0.35% | 24.91% | -15.44% |
| 2021 | -14.13% | -31.52% | 3.85% | 0.44% | -4.13% | -1.59% | 2.30% | 7.66% | -11.30% | -3.77% | -6.37% | 10.21% | -43.87% |
| 2020 | -29.89% | -7.86% | 1.07% | 2.53% | 10.49% | 4.66% | 2.67% | 19.76% | -1.59% | -18.82% | 25.91% | 7.91% | 3.31% |
| 2019 | -3.73% | 6.74% | -8.47% | -4.11% | -15.93% | -9.29% | 6.43% | 0.38% | -1.88% | 27.39% | 1.80% | 7.24% | 0.28% |
| 2018 | 63.73% | -18.40% | -0.61% | -5.71% | 5.07% | -22.27% | -2.61% | 30.45% | 2.84% | -27.30% | 32.49% | 15.29% | 48.36% |
| 2017 | -11.03% | 10.26% | 3.10% | -4.51% | 15.35% | -10.92% | -8.43% | 6.28% | -11.81% | 4.46% | 22.22% | 70.63% | 85.55% |
| 2016 | 2.28% | -2.97% | 38.70% | -12.15% | 9.12% | 21.04% | 5.00% | -9.07% | -8.23% | -35.87% | -1.27% | 12.88% | 0.00% |
| 2015 | 5.21% | 16.83% | 0.53% | 14.86% | 51.38% | 82.42% | -23.26% | -14.98% | 28.82% | -9.09% | 30.00% | -12.04% | 242.45% |
| 2014 | -4.08% | 6.75% | -3.98% | 4.15% | -4.10% | -2.81% | -1.63% | 1.53% | 12.08% | -11.11% | -2.02% | -1.03% | -7.91% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 009420.KS is 21, meaning it’s performing worse than 79% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Hanall Biopharma (009420.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Hanall Biopharma. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Hanall Biopharma was 80.64%, occurring on Aug 4, 2004. Recovery took 416 trading sessions.
The current Hanall Biopharma drawdown is 47.99%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -80.64% | Apr 25, 2001 | 806 | Aug 4, 2004 | 416 | Apr 4, 2006 | 1222 |
| -79.5% | Jul 14, 1997 | 225 | Jun 16, 1998 | 655 | Feb 15, 2001 | 880 |
| -72.14% | Sep 28, 2007 | 253 | Oct 8, 2008 | 519 | Nov 1, 2010 | 772 |
| -69.47% | Jan 31, 2018 | 1147 | Sep 28, 2022 | 308 | Dec 27, 2023 | 1455 |
| -68.09% | Aug 2, 2011 | 717 | Jun 25, 2014 | 244 | Jun 23, 2015 | 961 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Hanall Biopharma over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Hanall Biopharma, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -77.4%.
Valuation
The Valuation section provides an overview of how Hanall Biopharma is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 009420.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 009420.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 009420.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 009420.KS has a P/S ratio of 9.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 009420.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 009420.KS has a P/B value of 8.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |